id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-274810-vfr1g9kp	Lee, Meng	Covert COVID-19 complications: Continuing the use of evidence-based drugs to minimize potentially lethal indirect effects of the pandemic in stroke patients	2020-05-06		.txt	text/plain	750	39	49	However, actual situation might be even more dire, since such statistics likely do not fully display the entire impact of COVID-19, especially with regard to its influence on patients with a history of stroke who need to take cardiovascular drugs regularly to prevent recurrent vascular events. Clinical trial evidence shows that stroke patients with atrial fibrillation assigned to apixaban, a novel oral anticoagulant, compared with aspirin, had a substantially lower risk of recurrent stroke or systemic embolism (2.4% vs 9.6% per year, hazard ratio 0.29, 95% confidence interval [CI] 0.15 to 0.60). On the other hand, a large cohort study showed that discontinuation of aspirin was associated with a 40% increase in the risk of ischemic stroke compared with continuation of therapy in people taking aspirin for the secondary prevention of cardiovascular or cerebrovascular events. An Italian cohort study showed that in first-ever ischemic stroke patients who were 18 to 45 years, discontinuation of antihypertensive drugs was independent predictors of recurrent cardiovascular events.	./cache/cord-274810-vfr1g9kp.txt	./txt/cord-274810-vfr1g9kp.txt